Antidiabetic Agents

Multum Therapeutic Class Comparison, United States, 2019

Total Prescriptions in (2019)

Drug Name Total Prescriptions (2019) Percent Share
Metformin 85,739,443 41.8%
Insulin Glargine 19,211,654 9.4%
Glipizide 13,424,610 6.5%
Glimepiride 11,504,532 5.6%
Insulin Lispro 11,389,230 5.6%
Insulin Aspart 9,067,406 4.4%
Sitagliptin 8,866,812 4.3%
Insulin Detemir 5,534,526 2.7%
Dulaglutide 5,095,034 2.5%
Liraglutide 4,524,862 2.2%
Empagliflozin 4,459,539 2.2%
Insulin Degludec 3,632,526 1.8%
Metformin; Sitagliptin 3,363,544 1.6%
Pioglitazone 3,241,839 1.6%
Insulin Human; Insulin Isophane Human 2,528,165 1.2%
Semaglutide 2,021,061 1%
Linagliptin 1,941,245 0.9%
Glyburide 1,743,041 0.8%
Insulin Isophane 1,674,610 0.8%
Canagliflozin 1,373,540 0.7%
Insulin, Regular, Human 1,298,683 0.6%
Dapagliflozin 1,217,749 0.6%
Exenatide 1,202,897 0.6%
Insulin Aspart Protamine, Human 1,047,392 0.5%

Total Prescriptions by Drug Over Time

Drug Class Prescribing Trends Over Time


Prescription data source: Medical Expenditure Panel Survey (MEPS) 2013-2019. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 2021.10. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

ICU Trials: Summarized critical care trials at your fingertips
 
©2021 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Sep 12, 2021
Back to Top
Top